As the trend towards renewable energy, and especially solar power grows, companies are coming together to stake their claim on the market.
Earlier this week, two startups focused on solar financing made a deal to combine their assets and become a single company. As of the third quarter of 2015, Kilowatt Financial and Clean Power Finance will be one company, named Elevate Power.
The companies together will have 50,000 customers and $1.6 billion in financing for projects and loans. They believe this will give them a competitive edge over bigger companies like SolarCity and SunRun Inc.
Nat Kreamer, chief executive of Clean Power Finance states that the companies’ mission is to offer “great products that are faster and better by taking control of all the financing.”
The companies will offer both products and loans to help bring affordable solar power to more more U.S. consumers.
Some renewable energy analysts insist that low prices are the key for companies to gain market share. This start-up combination seems to be headed in that direction. This deal is a clear sign that the solar and renewable markets are in-demand and will be growing dramatically as costs continue to fall.
To continue reading…
Click here to read the Reuters article.
Until next time,
Keith Kohl
Check us out on YouTube!A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.
For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.
Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.
